These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29501396)
1. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors. Hu Z; Wang C; Han W; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML Bioorg Med Chem Lett; 2018 Apr; 28(6):987-992. PubMed ID: 29501396 [TBL] [Abstract][Full Text] [Related]
2. Macrocyclic factor XIa inhibitors. Wang C; Corte JR; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML Bioorg Med Chem Lett; 2017 Sep; 27(17):4056-4060. PubMed ID: 28780160 [TBL] [Abstract][Full Text] [Related]
3. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency. Corte JR; Yang W; Fang T; Wang Y; Osuna H; Lai A; Ewing WR; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Quan ML; Wexler RR; Lam PYS Bioorg Med Chem Lett; 2017 Aug; 27(16):3833-3839. PubMed ID: 28687203 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160 [TBL] [Abstract][Full Text] [Related]
5. Asymmetric Synthesis of Silanediol Inhibitors for the Serine Protease Coagulation Cascade Enzyme FXIa. Duong HQ; Sieburth SM J Org Chem; 2018 May; 83(10):5398-5409. PubMed ID: 29667397 [TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker. Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa. Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411 [TBL] [Abstract][Full Text] [Related]
8. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. Clark CG; Rossi KA; Corte JR; Fang T; Smallheer JM; De Lucca I; Nirschl DS; Orwat MJ; Pinto DJP; Hu Z; Wang Y; Yang W; Jeon Y; Ewing WR; Myers JE; Sheriff S; Lou Z; Bozarth JM; Wu Y; Rendina A; Harper T; Zheng J; Xin B; Xiang Q; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS Bioorg Med Chem Lett; 2019 Oct; 29(19):126604. PubMed ID: 31445854 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. Lei Y; Zhang B; Zhang Y; Dai X; Duan Y; Mao Q; Gao J; Yang Y; Bao Z; Fu X; Ping K; Yan C; Mou Y; Wang S Eur J Med Chem; 2021 Aug; 220():113437. PubMed ID: 33894565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]